SERENA-4: A Randomised, Multicentre, Double-Blind, Phase III
Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with
Estrogen Receptor-Positive, HER2-Negative Advanced Breast
Cancer Who Have Not Received Any Systemic Treatment for
The study is intended to show how safe and effective the combination of AZD9833 with palbociclib is in treating advanced/metastatic breast cancer compared to the alternative standard of care treatment (anastrozole in combination with palbociclib).
ER-positive, HER2-negative Advanced/Metastatic Breast Cancer
18 years or older
ER-positive, HER2-negative breast cancer
Previously untreated with any systemic anti-cancer therapy for locoregionally recurrent or metastatic ER+ disease
18 - 101
Healthy Volunteers Needed
Duration of Participation
You will receive the study drugs for as long as your cancer does not get worse or you do not have bad side effects. After you are done getting treated with the study drugs, we may contact you every 12 weeks until the study closes to see how you are doing and to ask about your cancer.
Knight Cancer Institute Clinical Trials